Literature DB >> 11207557

Stability of the Listeria monocytogenes ActA protein in mammalian cells is regulated by the N-end rule pathway.

M A Moors1, V Auerbuch, D A Portnoy.   

Abstract

Upon infection of mammalian cells, Listeria monocytogenes lyses the phagosome and enters the cytosol, where it secretes proteins necessary for its intracellular growth cycle. Consequently, bacterial proteins exposed to the cytosol are potential targets for degradation by host cytosolic proteases. One pathway for degradation of host cytosolic proteins, the N-end rule pathway, involves recognition of the N-terminal amino acid and is mediated by the proteasome. However, very few natural N-end rule substrates have been identified. We have examined the L. monocytogenes ActA protein as a potential target for this pathway. ActA is an essential determinant of L. monocytogenes pathogenesis that is required to induce actin-based motility and cell-to-cell spread. We show that the half-life of a secreted form of ActA can be altered in the mammalian cytosol by changing the N-terminal amino acid. Moreover, the introduction of a destabilizing N-terminus into the functional, surface-bound form of ActA results in a small-plaque phenotype in L2 cells, which is partially reversible by an inhibitor of the proteasome. These results indicate that the L. monocytogenes ActA protein is a natural N-end rule substrate, and that optimal function of ActA in mediating cell-to-cell spread is dependent upon its intracellular turnover rate.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11207557     DOI: 10.1046/j.1462-5822.1999.00020.x

Source DB:  PubMed          Journal:  Cell Microbiol        ISSN: 1462-5814            Impact factor:   3.715


  9 in total

1.  Listeria-derived ActA is an effective adjuvant for primary and metastatic tumor immunotherapy.

Authors:  Laurence M Wood; Zhen-Kun Pan; Vafa Shahabi; Yvonne Paterson
Journal:  Cancer Immunol Immunother       Date:  2010-03-06       Impact factor: 6.968

2.  Construction, characterization, and use of two Listeria monocytogenes site-specific phage integration vectors.

Authors:  Peter Lauer; Man Yin Nora Chow; Martin J Loessner; Daniel A Portnoy; Richard Calendar
Journal:  J Bacteriol       Date:  2002-08       Impact factor: 3.490

3.  Listeriolysin O secreted by Listeria monocytogenes into the host cell cytosol is degraded by the N-end rule pathway.

Authors:  Pamela Schnupf; Jianmin Zhou; Alexander Varshavsky; Daniel A Portnoy
Journal:  Infect Immun       Date:  2007-08-06       Impact factor: 3.441

4.  Mechanism of polarization of Listeria monocytogenes surface protein ActA.

Authors:  Susanne M Rafelski; Julie A Theriot
Journal:  Mol Microbiol       Date:  2006-02       Impact factor: 3.501

5.  Three regions within ActA promote Arp2/3 complex-mediated actin nucleation and Listeria monocytogenes motility.

Authors:  J Skoble; D A Portnoy; M D Welch
Journal:  J Cell Biol       Date:  2000-08-07       Impact factor: 10.539

Review 6.  Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy.

Authors:  Laurence M Wood; Yvonne Paterson
Journal:  Front Cell Infect Microbiol       Date:  2014-05-12       Impact factor: 5.293

7.  microRNA-125a-3p is regulated by MyD88 in Legionella pneumophila infection and targets NTAN1.

Authors:  Elisa Jentho; Malena Bodden; Christine Schulz; Anna-Lena Jung; Kerstin Seidel; Bernd Schmeck; Wilhelm Bertrams
Journal:  PLoS One       Date:  2017-04-26       Impact factor: 3.240

8.  T-Cell Responses to Immunodominant Listeria Epitopes Limit Vaccine-Directed Responses to the Colorectal Cancer Antigen, Guanylyl Cyclase C.

Authors:  John C Flickinger; Jagmohan Singh; Yanki Yarman; Robert D Carlson; Joshua R Barton; Scott A Waldman; Adam E Snook
Journal:  Front Immunol       Date:  2022-03-09       Impact factor: 8.786

Review 9.  Listeria monocytogenes as a Vector for Cancer Immunotherapy: Current Understanding and Progress.

Authors:  John C Flickinger; Ulrich Rodeck; Adam E Snook
Journal:  Vaccines (Basel)       Date:  2018-07-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.